Skip to main content

Advertisement

SpringerLink
Log in

Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01)

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC), apart from increasing breast conservation rates, also provides an opportunity to assess tumour response to chemotherapy, with Pathological Complete Response (pCR) described as an independent prognostic factor and a surrogate marker for better outcome and survival. Our primary aim was to identify clinical and pathological factors associated with pCR following NACT in patients with LABC treated at our institution. Our secondary aim was to analyze the impact of pCR and associated factors on disease free survival (DFS) and overall survival (OS). A retrospective analysis of LABC patients treated with NACT between Jun 2011 and Dec 2013. Clinical and histological variables were analyzed for association with pCR (no invasive or in situ carcinoma in breast or axillary lymph nodes). Kaplan-Meier curves and Cox regression model was used for survival analysis. All values were twosided, and statistical significance was defined as p < 0.05. 240 patients were included. The median tumor size was 6 cm, with T4 disease in 49.8 %. 45 % of tumors were of low grade (G1 + G2) and 53.8 % of high grade (G3). Estrogen Receptor (ER) was positive in 70.8 %, progesterone receptor (PR) in 53.3 % and Her2 in 38.8 %. The preferred NACT regimen was sequential anthracycline and taxane and 88.8 % of patients received this regimen. Of 93 potential Her2 Positive patients, only 23 received trastuzumab. Overall 23.2 % patients had pCR. At median follow up of 21 months (range, 3–42), 16.3 % of patients had recurrent disease, and 6.7 % had died. High tumor grade (p = 0.04), PR negative status (p < 0.01) and trastuzumab treatment (p = 0.01) were significant predictors of pCR in univariate analysis. On multivariate analysis PR negativity (OR 3.2, 95 % CI = 1.6 to 6.04, p = 0.001) and Trastuzumab use (OR 0.24, 95 % CI = 0.1 to 0.6, p = 0.004) were significant. Patients with pCR had positive associations with survival (p < .02,OS& .02,DFS) and interestingly PR positivity had positive association with DFS (p = 0.02) in Kaplan-Meier curves. On Cox regression, PR positivity (HR = 0.3, p < 0.01) and pCR (HR = 0.2, p < 0.01) correlated with DFS, though not with early OS. for the PR positive patients were paradoxical. Though less likely to have pCR (15 %, vs 32 % if PR negative), they had better DFS (p = 0.02), and achieving pCR had no survival benefit in this group. In contrast, PR negative patients, irrespective of ER status, had a high pCR rate, and achieving pCR had survival advantage (p < 0.05,DFS& p < 0.02,OS). PR negative patients without pCR had the worst DFS (p < 0.01) among all. High grade and Trastuzumab treatment as predictors of pCR, and pCR as a surrogate marker for survival are well recognized, and are supported by our findings. In present cohort, PR negativity showed prognostic importance independent of ER status. However these results were derived from sub-group, post-hoc analysis of data from a pre-existing cohort, without ‘a-priori’ hypothesis for survival analysis in relation to PR. These “hypothesis generating” results need confirmation by a well-designed prospective cohort or a randomized trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tewari M, Krishnamurthy A, Shukla HS (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 17:301–311

    Article  PubMed  Google Scholar 

  2. Colleoni M, Zahrieh D, Gelber RD, Viale G, Luini A, Veronesi P, et al. (2003) Preoperative systemic treatment: prediction of responsiveness. Breast 12:538–542

    Article  CAS  PubMed  Google Scholar 

  3. Guarneri V, Broglio K, Kau SW, et al. (2006) Prognostic value of pathological complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044

    Article  PubMed  Google Scholar 

  4. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785

    Article  PubMed  Google Scholar 

  5. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22:2303–2312

    Article  PubMed  Google Scholar 

  6. Hammond MEH, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Oncology Practice 6(4):195–197

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wolff AC, Hammond MEH, Hicks DG, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013

    Article  PubMed  Google Scholar 

  8. Tavassoli FA, Devilee P (2003) World Health Organization classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon

    Google Scholar 

  9. Von Minckwitz G, Untch M, Blohmer JU, et al. (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–804.24

    Article  Google Scholar 

  10. Carey LA, Dees EC, Sawyer L, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334

    Article  CAS  PubMed  Google Scholar 

  11. Cortazar P, Zhang L, Untch M, et al. (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172

    Article  PubMed  Google Scholar 

  12. Fumagalli D, Bedard PL, Nahleh Z, et al. (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 13:e240–e248. doi:10.1016/S1470-2045(11)70378-3

    Article  PubMed  Google Scholar 

  13. Kim MM, Allen P, Gonzalez-Angulo AM, et al. (2013) Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999–2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Peintinger F, Buzdar AU, Kuerer HM, et al. (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncology 19(12):2020–2025

    Article  CAS  Google Scholar 

  15. E. H. Lips, L. Mulder ,J. J. de Ronde ,I. A. M. Mandjes ,B. B. Koolen, L. F. A. Wessels, S. Rodenhuis, J. Wesseling. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response, Breast Cancer Res Treat 2013 140:63–71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. J. M. Perez Garcia, C. Saura, E. Muñoz, G. Sanchez-Olle, P. Gomez, V. Peg, D. Sabadell, J. Cortes, J. Baselga, M. Bellet. (2009) Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts). J Clin Oncol 27:15 s, (suppl; abstr 637)

  17. Baselga J, Bradbury I, Eidtmann H, et al. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 18:633–640

    Article  CAS  Google Scholar 

  18. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J¨r, Eidtmann H, Gerber B, Hanusch C, Ku¨hn T, du Bois A, Blohmer J-U, Thomssen C, Costa SD, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant TreatmentWith trastuzumab in HER2-positive breast cancer: results from the Gepar Quattro study. J Clin Oncol 28(12):2024–2031

    Article  CAS  PubMed  Google Scholar 

  19. Goldhirsch A, Wood WC, Coates AS, et al. (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32. doi:10.1016/S1470-2045(11)70336-9

    Article  CAS  PubMed  Google Scholar 

  21. Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y. (2014) High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer, Clin breast cancer Dec 24. pii: S1526–8209(14)00288–2. doi: 10.1016/j.clbc.2014.12.007.

  22. G. Cancello, P. Maisonneuve,, N. Rotmensz, G. Viale, M. Colleon, Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse: Ann Oncol, 2013:661–668

  23. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM (2014) Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. British Journal of Cancer 110:565–572. doi:10.1038/bjc.2013.756

    Article  CAS  PubMed  Google Scholar 

  24. Burstein HJ (2010) Ann Alexis Prestrud, Jerome Seidenfeld, Holly Anderson, Thomas a. Buchholz, Nancy E. Davidson, Karen E. Gelmon et al. “American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer.”Journal of. Clin Oncol JCO-2009

  25. Lamy P-J, Pujol P, Thezenas S, Kramar A, Guilleux PRF, Grenier J (2002) Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 76:65–71

    Article  CAS  PubMed  Google Scholar 

  26. Clark GM, McGuire WL, Hubay CA, et al. (1983) Progesterone receptor as a prognostic factor instage II breast cancer. N Engi J Med 309:1343–1347

    Article  CAS  Google Scholar 

  27. Daniel AR, Hagan CR, Lange CA (2011) Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab 6(3):359–369. doi:10.1586/eem.11.25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218

    Article  CAS  PubMed  Google Scholar 

  29. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomize trials. Lancet. 2005; 365:1687–1717. doi:10.1016/S0140–6736(05)66544–0.

Download references

Author information

Authors and Affiliations

  1. Department of Breast Oncosurgery, Tata Medical Centre, Kolkata, India

    Sanjit Agrawal & Rosina Ahmed

  2. Tata Medical Center, Kolkata, India

    Lalit Banswal, Animesh Saha & Soumitra Shankar Datta

  3. Department of Pathology, Tata Medical Center, Kolkata, India

    Indu Arun

  4. Radiation Oncology Department, Tata Medical Center, Kolkata, India

    Sanjoy Chatterjee

Authors
  1. Sanjit Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lalit Banswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Animesh Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Indu Arun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soumitra Shankar Datta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sanjoy Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rosina Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjit Agrawal.

Ethics declarations

Conflict of Interests

The authors have no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agrawal, S., Banswal, L., Saha, A. et al. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01). Indian J Surg Oncol 7, 397–406 (2016). https://doi.org/10.1007/s13193-016-0523-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0523-3

Keywords

Search

Navigation